Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio para investigar la seguridad y eficacia de la crema de tapinarof al 1% en participantes de 3 meses a <24 meses con dermatitis atópica (Adoring)

6 de noviembre de 2026 actualizado por: Organon and Co

Estudio aleatorizado, doble ciego, controlado con vehículo (Periodo 1) y de etiqueta abierta (Periodo 2) de fase 3 para investigar la seguridad y eficacia de la crema de tapinarof, 1% en participantes pediátricos de 3 meses a < 24 meses con dermatitis atópica

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Tipo de estudio

Intervencionista

Inscripción (Actual)

187

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Alberta
      • Calgary, Alberta, Canadá, T2J 7E1
        • Dermatology Research Institute
      • Red Deer, Alberta, Canadá, T4P 1K4
        • CARe Clinic (Central Alberta Research Clinic)
    • British Columbia
      • Surrey, British Columbia, Canadá, V3R 6A7
        • Dr. Chih-Ho Hong Medical Inc.
    • Manitoba
      • Winnipeg, Manitoba, Canadá, R3J 0S9
        • Manitoba Allergy Research Inc.
    • Nova Scotia
      • Halifax, Nova Scotia, Canadá, B3K 5R3
        • Maritime Dermatology
    • Ontario
      • Burlington, Ontario, Canadá, L7L 6W6
        • Halton Pediatric Allergy
      • Hamilton, Ontario, Canadá, L8S 1G5
        • Triple A Lab Inc.
      • Niagara Falls, Ontario, Canadá, L2H 1C4
        • Allergy Research Canada Inc.
    • Saskatchewan
      • Regina, Saskatchewan, Canadá, S4V 1R9
        • Dr. Rachel Asiniwasis Medical Professional Corporation
      • Saskatoon, Saskatchewan, Canadá, S7K 2C1
        • Skinsense Medical Research
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35209
        • AllerVie Clinical Research
    • Arkansas
      • Bryant, Arkansas, Estados Unidos, 72022
        • Dermatology Trial Associates
    • California
      • Los Angeles, California, Estados Unidos, 90045
        • Dermatology Research Associates
      • Sacramento, California, Estados Unidos, 95815
        • Integrative Skin Science and Research
      • San Diego, California, Estados Unidos, 92123
        • Allergy and Asthma Medical Group and Research Center
      • Thousand Oaks, California, Estados Unidos, 91320
        • Clinical Trials Research Institute
    • Colorado
      • Castle Rock, Colorado, Estados Unidos, 80109
        • Clarity Dermatology
    • Florida
      • Boca Raton, Florida, Estados Unidos, 33486
        • Skin Care Research, LLC.
      • Jacksonville, Florida, Estados Unidos, 32256
        • APEX Clinical Trials
      • Wellington, Florida, Estados Unidos, 33449
        • TruDerm Research
    • Georgia
      • Cumming, Georgia, Estados Unidos, 30040
        • Cleaver Medical Group Dermatology, Inc
    • Idaho
      • Meridian, Idaho, Estados Unidos, 83646
        • Ada West Research
    • Illinois
      • Skokie, Illinois, Estados Unidos, 60077
        • Endeavor Health Clinical Trials Center
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46250
        • Dawes Fretzin Clinical Research Group, LLC
      • Plainfield, Indiana, Estados Unidos, 46168
        • The Indiana Clinical Trials Center, PC
    • Kentucky
      • Bowling Green, Kentucky, Estados Unidos, 42104
        • Equity Medical, LLC
    • Maryland
      • Rockville, Maryland, Estados Unidos, 20850
        • Lawrence J Green, MD LLC
    • Michigan
      • Auburn Hills, Michigan, Estados Unidos, 48326
        • Oakland Hills Dermatology
    • Minnesota
      • New Brighton, Minnesota, Estados Unidos, 55112
        • Minnesota Clinical Study Center
    • Mississippi
      • Ridgeland, Mississippi, Estados Unidos, 39157
        • SKY Integrative Medical Center
    • Missouri
      • Saint Joseph, Missouri, Estados Unidos, 64506
        • MediSearch Clinical Trials
    • Nevada
      • Reno, Nevada, Estados Unidos, 89509
        • Skin Cancer and Dermatology Institute
    • New York
      • Kew Gardens, New York, Estados Unidos, 11415
        • Forest Hills Dermatology Group
      • New York, New York, Estados Unidos, 10012
        • Bobby Buka MD, PC
      • The Bronx, New York, Estados Unidos, 10455
        • Equity Medical, LLC
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27516
        • The University of North Carolina Dermatology and Skin Cancer Center
    • Ohio
      • Fairborn, Ohio, Estados Unidos, 45324
        • Dermatologists of Central States, LLC
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73120
        • Allergy Asthma and Clinical Research Center
    • Oregon
      • Portland, Oregon, Estados Unidos, 97210
        • Oregon Dermatology and Research Center
      • Portland, Oregon, Estados Unidos, 97239
        • Oregon Health & Science University
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Medical University of South Carolina
      • North Charleston, South Carolina, Estados Unidos, 29420
        • National Allergy and Asthma Research, LLC.
    • Texas
      • Bellaire, Texas, Estados Unidos, 77401
        • The University of Texas Health Science Center at Houston
      • Dallas, Texas, Estados Unidos, 75230
        • Dermatology Treatment and Research Center
      • Southlake, Texas, Estados Unidos, 76092
        • Stryde Research - Epiphany Dermatology
    • Washington
      • Spokane, Washington, Estados Unidos, 99202
        • Dermatology Specialists of Spokane

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

3 meses a 1 año (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
  • Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
  • Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
  • Legal guardian or primary caregiver is able and willing to adhere to protocol requirements

Exclusion Criteria:

  • Significant neurological disorder or history of seizure
  • Know clinically significant cardiac rhythm or cardiac disorder
  • History of sudden infant death in a sibling
  • Clinically significant chromosome abnormality
  • History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
  • Diseases that could cause pruritic and/or sleep disruption
  • Immunocompromised
  • Current chronic or acute infection requiring treatment
  • Use of prohibited medication(s) or procedure(s)
  • Use of prohibited medications by breastfeeding mother if breastfeeding participant

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Tapinarof cream

Tapinarof cream, 1%, applied topically once daily

Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.

Otros nombres:
  • DMVT-505
  • OG-0505
  • GSK2894512A
  • GSK28994512
  • STI-1001
  • WBI-1001
Comparador de placebos: Vehicle cream

Vehicle cream is applied topically once daily for up to 8-weeks.

Applied topically once daily to lesions on participant's skin during the Double-Blind period.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8
Periodo de tiempo: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period
Periodo de tiempo: Baseline to the end of the Open-Label Period, up to 56 weeks.

The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

Baseline to the end of the Open-Label Period, up to 56 weeks.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.
Periodo de tiempo: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the %BSA affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. A higher EASI score represents more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8
Periodo de tiempo: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

Assessment of %BSA is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% [10 handprints], upper extremities = 20% [20 handprints], trunk (including axillae and groin) = 30% [30 handprints], lower extremities, including buttocks, = 40% [40 handprints]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8
Periodo de tiempo: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

Severity Index (EASI) score from Baseline to Week 8 Description: The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Periodo de tiempo: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Periodo de tiempo: Baseline to the end of the Open-Label Period, up to 56 weeks

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to the end of the Open-Label Period, up to 56 weeks
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Periodo de tiempo: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Periodo de tiempo: Baseline to the end of the Open-Label Period, up to 56 weeks.

TEAEs are AEs that started on or after the first dose of study medication.

Baseline to the end of the Open-Label Period, up to 56 weeks.
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Periodo de tiempo: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Periodo de tiempo: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Periodo de tiempo: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Periodo de tiempo: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Clinical Lead Late-Stage Clinical Development, Organon and Co

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

29 de diciembre de 2025

Finalización primaria (Estimado)

1 de agosto de 2027

Finalización del estudio (Estimado)

1 de agosto de 2027

Fechas de registro del estudio

Enviado por primera vez

21 de noviembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

2 de diciembre de 2025

Publicado por primera vez (Actual)

4 de diciembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir